Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Coordination and Support Action · Finished

NIMBLE WOMENTECHEU A novel non-invasive and non-ionizing medical device for monitoring patients with implanted stents

Coordinator
Nimble Diagnostics SL, Spain
Runs
1 June 2023 to 31 May 2024
Status
Finished
EU funding
€75k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101113998

What the project is doing

In the project's own words, from its summary on CORDIS.

Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents. Stents are one of the most implanted devices worldwide and are used to restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but once implanted can become blocked or damaged, which occur in 30% of the cases.

The symptoms only appear after a stent is already 90% dysfunctional, which increases the incidenceof serious complications, including strokes, heart attacks or sudden death. The standard-of-care is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex procedure is not standardized for recurrent monitoring, not allowing clinicians to act upon the problem until it has already manifested.

The NIMBLE System can read the electromagnetic signature of the stent non-invasively, providing information on stent satus and malfunction that can be correlated with relevant clinical outcomes. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of pharmacological therapy, shifting from reactive to proactive care. Our technology is currently at TRL5 with an MVP that has shown and excellent results in on-going validations.

However, before we can offer our solution to cardiologists and primary care clinicians, we must complete key activities in our action plan. WomenTechEU will help us to better understand pricing and reimbursement strategies for the NIMBLE System in European markets, gain visibility with investors and collaborators, and support and mentoring from being one of the growing numbers of female entrepreneurs. Susana expects that this program supports her in bringing NIMBLE System to the market.

Topics

Who is involved

OrganisationCityCountryRole
Nimble Diagnostics SLBadalonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI